OUTbio UK is an independent network run specifically for the LGBTQ community and its allies within the biotech community in the UK.
Our mission is to connect LGBTQ professionals within the biotech community, provide mutual support and mentorship, share ideas about how to implement best practices within our companies and develop our own networks and friendships.
OUTbio UK is inspired by the work of OUTbio – a 1200+ member group with an aligned mission based in the USA. OUTbio began with a meeting of 10 people in Boston in 2015, and rapidly became the largest group of its kind in the industry.
We are the first international affiliate and hope to encourage others to form around the world, enabling members to build a global network.
Meet The Team
OutBio is currently supported by a small team of biotech executives from across the UK and from a range of backgrounds. if you'd like to join the team, please get in touch - there is plenty to be done!
Originally trained as a pharmacologist, Tim is a biotech investor and company builder.
He was part of the founding team at Autolus, Gyroscope, Casma Therapeutics, MiroBio via his investing roles at Syncona and Third Rock Ventures and Oxford Sciences Innovation
He is now a London Partner of the transatlantic venture firm Monograph Capital
Tim spent time in Boston where he first witnessed the benefits of an LGBTQ network for the biotech industry and he hopes to catalyse a similarly supportive environment in the UK.
Grant is an experienced operations and finance executive working across a number of biotechs in the Cambridge area.
Grant has over 20 years of experience with venture-backed companies and has acted as Founder/COO/CFO in recent years for companies including: NRG Therapeutics, Myricx, Alechemab, and Auspherix.
Grant was instrumental in founding OUTbio UK, with an ambition to improve the understanding of the LGBTQ community within the biotech industry.
Quin is an MD, with further degrees in genetics, mathematics, and computational biology, and a doctorate in systems genomics.
He has always loved biopharma, founding his first liver drug genomics company 15 years ago.
More recently he headed up the advanced genomics department for a large pharma before co-founding Ochre Bio, which uses genomic deep phenotyping to develop therapies for chronic diseases.
Quin also happens to think that OUTbio UK is an idea well overdue on this side of the pond.
Tom is a senior biotech communications consultant, with both in-house and agency experience assisting a wide variety of global clients.
Tom was formerly a Vice President at premier biotech consultancy Ten Bridge Communications, based in Boston, Massachusetts.
Prior to that, he served as Director of Communications at NASDAQ-listed drug developer Nexvet Biopharma. Originally hailing from Hong Kong and New Zealand, Tom holds a master's degree in biotech business (first class honours), and a bachelor's degree in biomedical science.
Tom is the Secretary of OUTbio, which is a registered non-profit in the United States.